Mesenteric venous thrombosis in adults
Executive Summary
Mesenteric venous thrombosis (MVT) is a form of acute mesenteric ischemia resulting from the thrombotic occlusion of one or more mesenteric veins. While historically considered a primary cause, it now accounts for approximately 10% of acute mesenteric ischemia cases due to improved diagnostic differentiation. The condition's presentation varies significantly, manifesting in acute, subacute, or chronic forms, each with distinct clinical features. Acute MVT is characterized by severe abdominal pain disproportionate to physical findings, whereas chronic MVT is often asymptomatic or presents with complications of portal hypertension.
The diagnosis of MVT requires a high index of suspicion and is definitively established through imaging studies, with computed tomography (CT) recommended as the initial screening tool and magnetic resonance (MR) venography being the most reliable method. The etiology of MVT is multifactorial, with most patients having at least one predisposing risk factor, which can be acquired (e.g., pancreatitis, malignancy, recent surgery) or inherited (e.g., Factor V Leiden, prothrombin gene mutation).
Management of acute and subacute MVT is predominantly conservative, centered on systemic anticoagulation to prevent thrombus extension and promote recanalization, alongside supportive care including bowel rest and fluid resuscitation. Surgical intervention is reserved for patients with signs of bowel infarction or perforation. Anticoagulation therapy has dramatically improved outcomes, with studies showing an 80% vascular recanalization rate in treated patients and a reduction in modern mortality rates for acute MVT to between 10% and 20%. The prognosis for MVT is considerably better than that for acute arterial mesenteric ischemia and is closely tied to the presence of underlying conditions like malignancy or cirrhosis.
1.0 Introduction and Epidemiology
Acute mesenteric ischemia is defined as the sudden onset of intestinal hypoperfusion. Mesenteric venous thrombosis (MVT), an occlusion of the mesenteric veins, is one cause of this condition. MVT can present acutely, subacutely, or chronically.
Prevalence: The proportion of acute mesenteric ischemia cases attributed to MVT has decreased over time with improved differentiation from arterial and nonocclusive forms. MVT now accounts for approximately 10% of all cases of acute mesenteric ischemia. Other reviews place the figure between 2% and 10%.
Incidence: A time cohort study from Sweden (1970-2006) observed an increase in the incidence of MVT from 2.0 to 2.7 per 100,000 patient-years. This rise was attributed to the increased diagnostic use of computed tomography (CT).
Chronic MVT: The incidence of chronic MVT is reported less frequently than acute forms. However, in reviews that included both types, chronic or acute-on-chronic MVT accounted for 24% to 40% of the total MVT cases.
Demographics: The average age of presentation for MVT is between 45 and 60 years old, with a slight predominance in males.
2.0 Pathophysiology
The development of MVT is governed by Virchow's triad: stasis of blood flow, vascular injury, and hypercoagulability.
Anatomical Involvement: MVT almost exclusively involves the superior mesenteric vein (SMV) drainage system, affecting the distal small intestine. The inferior mesenteric vein (IMV), which drains the colon, is rarely involved, possibly due to robust collateral circulation.
Ileum: 64% to 83% of cases
Jejunum: 50% to 81% of cases
Colon: 14% of cases
Duodenum: 4% to 8% of cases
Physiological Cascade:
Occlusion: A thrombus acutely blocks one or more mesenteric veins.
Increased Resistance: This blockage increases perfusion resistance in the mesenteric venous bed.
Edema: As venous pressure rises, fluid effuses from the vasculature into the intestinal tissues, causing profound bowel wall edema and submucosal hemorrhage.
Ischemia & Infarction: The sequestration of fluid into the bowel lumen leads to systemic hypovolemia and hypotension. This reduces arterial flow, which exacerbates the ischemia. If venous arcades and vasa recta are completely occluded, bowel infarction can occur.
Collateral Circulation: In chronic MVT, dilated venous collaterals often develop. These can be a source of bleeding.
3.0 Risk Factors
MVT is a multifactorial condition predisposed by a range of acquired and inherited risk factors. Most patients who present with MVT have at least one identifiable predisposing factor.
Idiopathic Cases: While some series report idiopathic rates of 21% to 49%, closer examination often reveals underlying causes. Up to one-third of these patients may have a coexistent heritable thrombophilia.
Associated Conditions:
Prior VTE: A previous history of deep vein thrombosis (DVT) is reported in 20% to 40% of patients with MVT.
Malignancy: Reported in 4% to 16% of patients with acute MVT.
Myeloproliferative Disorders: Identified in 8% to 18% of patients with either acute or chronic MVT.
4.0 Clinical Presentation
The clinical features of MVT are determined by the location and timing of the thrombus formation and can be categorized into three main presentations.
4.1 Acute MVT
Symptoms: Characterized by the onset of colicky, periumbilical abdominal pain that is often described as being out of proportion to the findings on physical examination, at least initially. The onset is typically less sudden than in other forms of mesenteric ischemia.
Duration: Over 75% of patients report pain for at least two days before seeking medical attention, with a typical symptom duration ranging from 5 to 14 days.
Associated Findings: Approximately half of patients experience nausea and vomiting. The abdominal exam may reveal distension, and occult blood may be found in the stool.
Progression: Signs of peritoneal inflammation (e.g., rebound tenderness) are usually absent unless the bowel has become ischemic. As the condition progresses, bowel sounds may become absent, and peritoneal signs will develop.
4.2 Subacute MVT
Symptoms: The presentation is more insidious, with nonspecific abdominal pain that can persist for days to weeks. This may be the only feature.
Pathogenesis: This form occurs when venous occlusion is sufficient to cause ischemia, but collateral blood vessels are adequate to allow for recovery. However, some patients can progress to acute intestinal infarction requiring surgical intervention.
4.3 Chronic MVT
Symptoms: Patients are frequently asymptomatic, and the diagnosis is often made incidentally on imaging performed for unrelated reasons.
Symptomatic Presentation: When symptoms do occur, they are typically related to complications of portal hypertension, such as variceal bleeding, due to concomitant portal or splenic vein thrombosis. Some patients may experience intermittent abdominal pain after eating.
5.0 Diagnosis and Imaging
There are no clinical features specific to MVT, making a high index of suspicion essential for early diagnosis. A thorough review of the patient's personal and family medical history can increase suspicion.
Initial Assessment: Plain abdominal radiographs are nonspecific and may be completely normal in over 25% of patients. Findings suggestive of mesenteric ischemia include ileus with distended bowel loops, bowel wall thickening, and pneumatosis intestinalis.
Definitive Imaging: A definitive diagnosis is established with imaging studies that demonstrate thrombosis within the mesenteric veins.
Computed Tomography (CT): CT of the abdomen with and without oral and intravenous contrast is the recommended initial screening study due to its widespread availability and high accuracy (at least 90% in retrospective studies). Key findings include venous filling defects, enhanced bowel wall, mesenteric stranding, bowel wall thickening (>3 mm), and signs of infarction like intestinal pneumatosis or portal vein gas.
Magnetic Resonance (MR) Venography: This is considered the most reliable imaging study for the diagnosis of MVT, though motion artifacts can sometimes limit its accuracy.
Angiography: CT angiography (with delayed venous phase), MR angiography, or standard catheter-based angiography is suggested for patients with a nondiagnostic CT but persistent clinical suspicion.
Doppler Ultrasound: While widely available and noninvasive, it lacks sensitivity and specificity, particularly for thrombosis in smaller mesenteric vessels.
Hypercoagulability Testing: After MVT is diagnosed, hypercoagulable testing is suggested for all patients to identify predisposing conditions, which informs the duration of anticoagulation and allows for family education. Testing should include panels for inherited and acquired thrombophilias (e.g., protein C/S, Factor V Leiden, lupus anticoagulant).
6.0 Treatment Strategies
The management of established MVT is primarily conservative, with surgical intervention reserved for specific indications.
6.1 Nonoperative Management
Target Population: Patients with acute or subacute MVT without indications for urgent surgery can be managed safely with observation and medical therapy.
Core Components:
Systemic Anticoagulation: The cornerstone of treatment.
Bowel Rest: To reduce metabolic demand on the intestine.
Intravenous Fluid Administration: To correct hypovolemia.
Bowel Decompression: Often via nasogastric tube.
Prophylactic Antibiotics: Often given to limit bacterial translocation, a practice based on animal studies.
Chronic MVT Management: Initial management for symptomatic chronic MVT focuses on controlling complications like variceal bleeding.
6.2 Anticoagulation Therapy
Goal: To limit the propagation of the thrombus and allow for recanalization of the affected vessel. Initiation of therapy should not be delayed. The risk of bleeding from anticoagulation appears to be less than 10%.
Agents: Hospitalized patients are typically started on unfractionated heparin or low-molecular-weight heparin (LMWH), followed by a transition to an oral anticoagulant (e.g., warfarin, direct oral anticoagulants) once stable.
Duration:
Minimum 3-6 Months: Recommended for most patients.
6 Months: For patients with transient or correctable risk factors.
Long-Term/Indefinite: For patients with uncorrectable risk factors such as malignancy or an inherited thrombophilia.
Efficacy: Anticoagulation has been shown to dramatically improve outcomes.
Mortality: Reduced from 50% to 0% in one study of patients receiving postoperative anticoagulation.
Recanalization: Achieved in 80% of anticoagulated patients compared to less than 10% in those not anticoagulated.
Survival: Improved survival was noted in anticoagulated patients versus non-anticoagulated patients (59% vs 22% in one study).
6.3 Surgical Intervention (Abdominal Exploration)
Indications: Surgery should not be delayed for patients with overt signs of intestinal necrosis or perforation.
Approach: An open approach (laparotomy) is preferred over a laparoscopic approach, as bowel edema and distension can exacerbate mesenteric venous hypertension with insufflation.
Second-Look Operation: Because of the difficulty in assessing bowel viability and the high recurrence rate of gangrene, a planned "second-look" surgery is often advocated. It is typically performed 12 to 48 hours after the initial operation to reassess intestinal viability. In one series, a second look was performed on 31 patients, and 14 required further resection due to new gangrene.
6.4 Thrombolysis and Thrombectomy
These catheter-based techniques are considered an adjunct to anticoagulation and should be regarded as experimental. They may be reasonable for well-selected patients with severe disease who have an inadequate response to anticoagulation but no signs of bowel necrosis.
Transvenous Approach: In one series of 28 patients, 82% achieved complete or partial lysis, and 87% had symptom improvement. No patients required intestinal resection.
Transarterial Approach: A retrospective study of 32 patients showed that catheter-directed thrombolysis plus anticoagulation led to significantly better outcomes than postoperative anticoagulation alone, including higher rates of complete thrombus resolution (80% vs 20%), lower need for bowel resection (13% vs 59%), and improved one-year survival (93% vs 53%). However, clinically significant bleeding was higher in the thrombolysis group (20% vs 12%).
7.0 Monitoring and Post-Treatment Care
In-Hospital Monitoring: Patients require close observation with serial abdominal examinations and laboratory studies (CBC, electrolytes, lactate) to monitor for clinical worsening. Follow-up abdominal CT scans are often performed within 24-48 hours to exclude transmural necrosis.
Postoperative Care: The average length of hospitalization is 13 to 23 days. Oral nutrition is gradually advanced once the patient is clinically stable. Long-term anticoagulation is advocated for a minimum of six months.
Recurrence Risk: For patients who stop long-term oral anticoagulation, the risk of recurrent venous thromboembolism is approximately 15%.
8.0 Morbidity, Mortality, and Prognosis
Prognosis: Acute MVT carries a better prognosis than other forms of acute mesenteric ischemia.
A large systematic review found an overall mortality rate of 44% for MVT, compared with 66% to 89% for arterial occlusive or nonocclusive ischemia.
Modern Mortality Rates: With prompt diagnosis and anticoagulation, mortality rates for acute MVT in modern studies are between 10% and 20%. Rates are significantly higher (over 75%) for patients who present with intestinal infarction.
Chronic MVT Prognosis: The prognosis is related to the severity of any underlying illness, such as malignancy. For patients without cirrhosis or malignancy, the three-year survival rate may be as high as 93%. Overall survival rates of 78% to 83% over five years have been reported.
Long-Term Complications:
Recurrent Symptoms: The recurrence rate appears low while patients are on anticoagulation.
Intestinal Stricture: The development of a small bowel stricture is a possible complication during the chronic phase after recovery from acute MVT.
